Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 aPriori aPriori +195.44%
#4 Bedrock Bedrock +78.59%
#5 Cysic Cysic +52.73%
#6 Prom Prom +41.94%
#7 Playnance Playnance +35.03%
#8 Bitway Bitway +27.63%
#9 Nillion Nillion +23.82%
#10 COTI COTI +23.81%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Pharnext S.A. Pharnext S.A.

Pharnext S.A.

ALPHA
Rank in Stocks #42432
Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm... Based in France, Pharnext SA is a clinical-stage biopharmaceutical firm dedicated to creating treatments for a range of neurodegenerative disorders, encompassing both rare (orphan) and common forms. Its pipeline features SYNGILITY, which has advanced through Phase III trials for Charcot-Marie-Tooth disease type 1A (CMT1A). Additionally, PXT864 has concluded Phase II clinical studies for Alzheimer's disease, and is also being explored for its potential in Parkinson's disease and amyotrophic lateral sclerosis (ALS). Pharnext also innovates with PLEOTHERAPY, a proprietary platform that harnesses big genetic data and artificial intelligence. In a collaborative effort, the company holds an agreement with the University Hospital Institute Mediterranee Infection to assess existing pharmaceuticals for their potential application against the COVID-19 virus. The organization was established in 2007, with its main offices located in Issy-Les-Moulineaux, France.
Share Price
$0.00023723
Last synced: 2024-08-26
Market Cap
$1.41K
Change (1 day)
111.67%
Change (1 year)
0.00%
Country
FR
Trade Pharnext S.A. (ALPHA)

Category

Healthcare
Revenue for Pharnext S.A. (ALPHA)
Revenue in Dec 2023 TTM: $-487.61K
According to Pharnext S.A. latest financial reports the company's current revenue (TTM) is $-487.61K. In 2022 the company made a revenue of $598.55 a decrease compared to the revenue in the year 2021 that was $96.41K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Pharnext S.A. from 2013 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $-487.61K -4,510.88%
2023 $11.05K 1,746.90%
2022 $598.55 -99.38%
2021 $96.41K 98.76%
2020 $48.51K -82.90%
2019 $283.61K -96.39%
2018 $7.85M 96.92%
2017 $3.99M -14.33%
2016 $4.65M 62.80%
2015 $2.86M -14.35%
2014 $3.34M -7.92%
2013 $3.62M 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -2,589,130.69%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -1,234,964.32%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -2,073,651.57%
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR